Biobetters Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
이 보고서는 Persistence Market Research의 세계 바이오베터 시장에 대한 심층 분석 및 예측을 담은 시장 조사 보고서입니다. 이 종합적인 보고서는 주요 시장 동향, 시장 동인 및 촉진요인, 새로운 트렌드에 대한 귀중한 통찰력을 제공합니다. 이 보고서는 바이오 제약 산업의 바이오베터 분야에 대한 자세한 개요를 제공하고 2024년부터 2031년까지 시장 성장 궤적을 예측하는 독점 데이터와 통계를 제시합니다.
주요 인사이트
- 바이오베터 시장 규모(2024년) : 657억 5,000만 달러
- 예상 시장 가치(2031년) : 1,171억 달러
- 세계 시장 성장률(2024-2031년 CAGR) : 8.6%
바이오베터 시장 - 조사 범위
바이오베터 시장에는 바이오베터 또는 바이오슈페리어로 알려진 기존 생물학적 제제를 개선하기 위해 설계된 다양한 바이오의약품 제품 및 치료 방식이 포함됩니다. 이 시장은 바이오 제약사, CRO, 규제 당국 및 의료 서비스 제공업체에게 치료 효과, 안전성 및 환자 결과를 향상시키는 혁신적인 바이오베터 제제, 전달 시스템 및 제조 기술을 제공합니다. 바이오베터는 생물학적 제제의 진화된 형태로, 참조 생물학적 제제 대비 약동학을 최적화하고 면역원성을 낮추며 환자의 편의성을 향상시킵니다. 시장 개척의 원동력은 바이오베터 요법에 대한 수요 증가, 생물학적 제제의 특허 만료, 바이오시밀러 및 바이오베터의 개발 및 승인을 촉진하는 규제 당국의 동향입니다.
시장 성장 촉진요인 :
세계 바이오베터 시장은 몇 가지 주요 성장 촉진요인의 혜택을 받고 있습니다. 바이오 제약사들은 오리지널 바이오의약품에 비해 효능, 안전성, 투여 요법 개선 등 향상된 치료 프로파일을 가진 바이오베터 후보물질을 개발하기 위해 연구개발에 투자하고 있습니다. 또한, 바이오프로세스 기술, 단백질 공학 및 제제 과학의 발전으로 원하는 특성과 성질을 가진 바이오베터 분자를 설계하고 최적화할 수 있게 되었습니다. 또한, 바이오시밀러 의약품의 가용성 증가와 규제 프레임워크의 개선은 바이오베터 분야의 혁신과 경쟁을 촉진하고 있습니다. 또한, 만성질환 증가, 개인맞춤형 의료에 대한 관심, 환자 중심의 치료모델은 환자 개개인의 필요와 치료 선호도에 맞춘 바이오베터 치료의 기회를 창출하고 있습니다.
시장 성장 억제요인
성장 가능성이 높은 바이오베터 시장은 개발 비용, 규제 요건, 시장 접근성 등의 문제에 직면해 있습니다. 바이오베터 개발은 전임상 및 임상시험, 생산 규모 확대, 규제 당국 신청 등 높은 비용과 복잡성을 수반하기 때문에 투자를 억제하고 시장 진입을 지연시킬 수 있습니다. 또한, 바이오베터 후보물질의 비교가능성, 안전성, 유효성을 입증해야 하는 까다로운 규제 기준은 규제상의 장애물과 불확실성을 야기합니다. 또한, 바이오시밀러, 제네릭 및 혁신적 바이오의약품과 시장 경쟁은 바이오베터 제품의 가격 책정, 상환 및 시장 점유율에 영향을 미칠 수 있습니다. 이러한 장벽을 극복하기 위해서는 개발 경로를 간소화하고, 혁신에 대한 인센티브를 부여하며, 바이오베터 치료제에 대한 환자 접근성을 보장하기 위해 업계 이해관계자, 규제 당국 및 의료 지불자의 협력이 필요합니다.
시장 기회
바이오베터 시장은 기술 혁신, 시장 차별화, 치료 혁신으로 인해 큰 성장 기회를 맞이하고 있습니다. 정밀의료, 표적 약물 전달, 맞춤형 생물학적 제제 등의 새로운 트렌드는 바이오베터 개발 및 상업화에 새로운 길을 열어줄 것입니다. 나노 입자, 미셀, 항체 약물 복합체(ADC)와 같은 새로운 약물 전달 시스템의 통합은 바이오베터 분자의 약동학, 조직 표적화 및 치료 지수를 향상시킬 것입니다. 또한 피하주사, 경구용 정제, 자동주사기 등 환자 중심의 제형 채택은 치료 순응도, 편의성, 환자 만족도를 향상시킬 수 있습니다. 또한 전략적 파트너십, 라이선스 계약 및 공동 개발 제휴를 통해 기업은 바이오베터 발굴, 최적화 및 상업화를 위해 상호보완적인 전문 지식, 자원 및 역량을 활용할 수 있습니다.
본 보고서에서 다룬 주요 질문들
- 바이오베터 시장의 가치는?
- 바이오베터 시장 성장 억제요인은 무엇인가?
- 시장을 이끄는 주요 요인은?
- 시장의 주요 기업은?
목차
제1장 주요 요약
제2장 시장 개요
제3장 주요 시장 동향
- 시장에 영향을 미치는 주요 동향
- 제품 혁신/개발 동향
제4장 주요 성공 요인
- 최근의 제품 릴리스
- 제조업체의 프로모션 전략
- 규제 시나리오
제5장 세계의 바이오베터 시장 수요 분석
- 과거 시장가치 분석(2019년-2023년)
- 현재 및 향후 시장가치 예측(2024년-2031년)
제6장 시장 배경
- 거시경제 요인
- 예측 요인 - 관련성과 영향
- 시장 역학
제7장 세계의 바이오베터 시장 분석 : 제품 유형별
- 서론/주요 조사 결과
- 과거 시장 규모 분석(2019년-2023년) : 제품 유형별
- 현재 및 향후 시장 규모 분석과 예측(2024년-2031년) : 제품 유형별
- Erythropoietin Biobetters
- G-CSF Biobetters
- Interferon Biobetters
- Insulin Biobetters
- Monoclonal Antibodies Biobetters
- Anti-haemophilic Factor
- 기타
- 제품 유형별 시장의 매력 분석
제8장 세계의 바이오베터 시장 분석 : 적응증별
- 서론/주요 조사 결과
- 과거 시장 규모 분석(2019년-2023년) : 적응증별
- 현재 및 향후 시장 규모 분석과 예측(2024년-2031년) : 적응증별
- 당뇨병
- 암
- 신장병
- 신경 퇴행성 질환
- 유전성 질환(혈우병)
- 기타
- 적응증별 시장의 매력 분석
제9장 세계의 바이오베터 시장 분석 : 투여 경로별
- 서론/주요 조사 결과
- 과거 시장 규모 분석(2019년-2023년) : 투여 경로별
- 현재 및 향후 시장 규모 분석과 예측(2024년-2031년) : 투여 경로별
- 투여 경로별 시장의 매력 분석
제10장 세계의 바이오베터 시장 분석 : 유통 채널별
- 서론/주요 조사 결과
- 과거 시장 규모 분석(2019년-2023년) : 유통 채널별
- 현재 및 향후 시장 규모 분석과 예측(2024년-2031년) : 유통 채널별
- 유통 채널별 시장의 매력 분석
제11장 바이오베터 시장 분석 : 지역별
- 서론
- 과거 시장 규모 분석(2019년-2023년) : 지역별
- 현재 시장 규모 분석과 예측(2024년-2031년) : 지역별
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카
- 지역별 시장의 매력 분석
제12장 북미의 바이오베터 시장가치 분석
제13장 라틴아메리카의 바이오베터 시장가치 분석
제14장 유럽의 바이오베터 시장가치 분석
제15장 남아시아의 바이오베터 시장가치 분석
제16장 동아시아의 바이오베터 시장가치 분석
제17장 오세아니아바이오베터즈 시장가치 분석
제18장 중동 및 아프리카의 바이오베터 시장가치 분석
제19장 시장 구조 분석
- 기업 Tier별 시장 분석
- 주요 기업의 시장 점유율 분석
- 시장 입지 분석
제20장 경쟁 분석
- 경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 상세
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Merck &Co. Inc.
- Sanofi SA
- SERVIER
- Porton Biopharma Limited
- Eli Lily and Company
- Novo Nordisk A/S
- Biogen Inc.
- CSL Behring GmbH
- Teva Pharmaceutical Industries Ltd.
제21장 전제와 두자어
제22장 조사 방법
LSH
Persistence Market Research, a renowned market research firm, has conducted an in-depth analysis of the global Biobetters Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the biobetters segment within the biopharmaceutical industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2031.
Key Insights:
- Biobetters Market Size (2024): USD65.75 Bn
- Projected Market Value (2031): USD117.1 Bn
- Global Market Growth Rate (CAGR 2024 to 2031): 8.6%
Biobetters Market - Report Scope:
The Biobetters Market encompasses a diverse range of biopharmaceutical products and therapeutic modalities designed to improve upon existing biologic drugs, known as biobetters or biosuperiors. This market serves biopharmaceutical companies, contract research organizations (CROs), regulatory agencies, and healthcare providers, offering innovative biobetter formulations, delivery systems, and manufacturing technologies for enhanced therapeutic efficacy, safety, and patient outcomes. Biobetters represent an evolution of biologic drugs, offering optimized pharmacokinetics, reduced immunogenicity, and improved patient convenience compared to their reference biologics. Market growth is driven by increasing demand for biobetter therapies, patent expirations of biologic drugs, and regulatory pathways facilitating the development and approval of biosimilars and biobetters.
Market Growth Drivers:
The global Biobetters Market benefits from several key growth drivers. Biopharmaceutical companies are investing in research and development to develop biobetter candidates with enhanced therapeutic profiles, such as improved efficacy, safety, and dosing regimens, compared to originator biologics. Moreover, advancements in bioprocessing technologies, protein engineering, and formulation science enable the design and optimization of biobetter molecules with desired properties and characteristics. Additionally, the increasing availability of biosimilar reference products and supportive regulatory frameworks encourage innovation and competition in the biobetters space. Furthermore, the growing prevalence of chronic diseases, personalized medicine initiatives, and patient-centric care models create opportunities for biobetter therapies tailored to individual patient needs and treatment preferences.
Market Restraints:
Despite its promising growth prospects, the Biobetters Market faces challenges related to development costs, regulatory requirements, and market access. The high cost and complexity of biobetter development, including preclinical and clinical studies, manufacturing scale-up, and regulatory submissions, may deter investment and delay market entry. Moreover, stringent regulatory standards for demonstrating comparability, safety, and efficacy of biobetter candidates compared to reference biologics impose regulatory hurdles and uncertainty. Additionally, market competition from biosimilars, generics, and innovative biologics may impact pricing, reimbursement, and market share for biobetter products. Addressing these barriers requires collaboration between industry stakeholders, regulatory agencies, and healthcare payers to streamline development pathways, incentivize innovation, and ensure patient access to biobetter therapies.
Market Opportunities:
The Biobetters Market presents significant growth opportunities driven by technological innovations, market differentiation, and therapeutic innovation. Emerging trends such as precision medicine, targeted drug delivery, and personalized biologics offer new avenues for biobetter development and commercialization. The integration of novel drug delivery systems, such as nanoparticles, micelles, and antibody-drug conjugates (ADCs), enhances the pharmacokinetics, tissue targeting, and therapeutic index of biobetter molecules. Moreover, the adoption of patient-centric formulations, such as subcutaneous injections, oral tablets, and autoinjectors, improves treatment adherence, convenience, and patient satisfaction. Furthermore, strategic partnerships, licensing agreements, and co-development collaborations enable companies to leverage complementary expertise, resources, and capabilities for biobetter discovery, optimization, and commercialization.
Key Questions Answered in the Report:
- How much is the Biobetters Market worth?
- What are the restraints in the Biobetters Market?
- What are the key factors driving the market?
- Who are the top players in the market?
Competitive Intelligence and Business Strategy:
Leading players in the global Biobetters Market, including biopharmaceutical companies, CROs, and contract manufacturing organizations (CMOs), focus on innovation, collaboration, and market expansion to gain a competitive edge. These companies invest in research and development to discover and develop biobetter candidates with superior clinical profiles, such as improved efficacy, safety, and patient convenience. Moreover, strategic partnerships with academic research institutions, technology providers, and regulatory consultants enable companies to access novel technologies, scientific expertise, and regulatory insights to accelerate biobetter development and commercialization. Furthermore, emphasis on manufacturing optimization, supply chain efficiency, and cost-effective production processes enhances product quality, affordability, and global market access in the competitive landscape of biobetter therapies.
Key Companies Profiled:
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Sanofi SA
- SERVIER
- Porton Biopharma Limited
- Eli Lily and Company
- Novo Nordisk A/S
- Biogen Inc.
- CSL Behring GmbH
- Teva Pharmaceutical Industries Ltd.
Biobetters Market Research Segmentation:
Biobetters Market by By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Biobetters Market By Molecule Type
- G-CSF Biobetters
- Insulin Biobetters
- Erythropoietin Biobetters
- Monoclonal Antibodies Biobetters
- Others
Biobetters Market by Disease Indication
- Cancer
- Diabetes
- Genetic disease
- Neurological Disorders
- Others
Biobetters Market by Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)"
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Market Analysis
- 1.3. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
4. Key Success Factors
- 4.1. Recent Product Launches
- 4.2. Promotional Strategies, by Manufacturers
- 4.3. Regulatory Scenario
5. Global Biobetters Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031
- 5.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
- 5.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 5.2.1. Y-o-Y Growth Trend Analysis
- 5.2.2. Absolute $ Opportunity Analysis
6. Market Background
- 6.1. Macro-Economic Factors
- 6.1.1. Global Healthcare Spending Outlook
- 6.1.2. Global Pharmaceutical Outlook
- 6.1.3. Regional Healthcare Market Outlook
- 6.2. Forecast Factors - Relevance & Impact
- 6.2.1. Innovation of New Products
- 6.2.2. Increasing Research & Developmental Activities
- 6.2.3. Increasing Number of Biotechnology Industries And Research Institutes
- 6.2.4. Adoption of New Technologies In Research Field
- 6.3. Market Dynamics
- 6.3.1. Drivers
- 6.3.2. Restraints
- 6.3.3. Opportunity Analysis
7. Global Biobetters Market Analysis 2019-2023 and Forecast 2024-2031, by Product Type
- 7.1. Introduction / Key Findings
- 7.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2019-2023
- 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
- 7.3.1. Erythropoietin Biobetters
- 7.3.2. G-CSF Biobetters
- 7.3.3. Interferon Biobetters
- 7.3.4. Insulin Biobetters
- 7.3.5. Monoclonal Antibodies Biobetters
- 7.3.6. Anti-haemophilic Factor
- 7.3.7. Others
- 7.4. Market Attractiveness Analysis By Product Type
8. Global Biobetters Market Analysis 2019-2023 and Forecast 2024-2031, By Indication
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2031
- 8.3.1. Diabetes
- 8.3.2. Cancer
- 8.3.3. Renal Disease
- 8.3.4. Neurodegenerative Disease
- 8.3.5. Genetic Disorders (Haemophilia)
- 8.3.6. Others
- 8.4. Market Attractiveness Analysis By Indication
9. Global Biobetters Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2031
- 9.3.1. Subcutaneous
- 9.3.2. Intravenous
- 9.4. Market Attractiveness Analysis By Route of Administration
10. Global Biobetters Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Biobetters Market Analysis 2019-2023 and Forecast 2024-2031, by Region
- 11.1. Introduction
- 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
- 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. MEA
- 11.4. Market Attractiveness Analysis By Region
12. North America Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 12.3.1. By Country
- 12.3.1.1. U.S.
- 12.3.1.2. Canada
- 12.3.2. By Product Type
- 12.3.3. By Indication
- 12.3.4. By Route of Administration
- 12.3.5. By Distribution Channel
- 12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Product Type
- 12.4.3. By Indication
- 12.4.4. By Route of Administration
- 12.4.5. By Distribution Channel
- 12.5. Key Market Participants - Intensity Mapping
- 12.6. Drivers and Restraints - Impact Analysis
13. Latin America Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 13.3.1. By Country
- 13.3.1.1. Brazil
- 13.3.1.2. Mexico
- 13.3.1.3. Rest of Latin America
- 13.3.2. By Product Type
- 13.3.3. By Indication
- 13.3.4. By Route of Administration
- 13.3.5. By Distribution Channel
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Product Type
- 13.4.3. By Indication
- 13.4.4. By Route of Administration
- 13.4.5. By Distribution Channel
- 13.5. Key Market Participants - Intensity Mapping
- 13.6. Drivers and Restraints - Impact Analysis
14. Europe Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 14.3.1. By Country
- 14.3.1.1. Germany
- 14.3.1.2. Italy
- 14.3.1.3. France
- 14.3.1.4. U.K.
- 14.3.1.5. Spain
- 14.3.1.6. BENELUX
- 14.3.1.7. Russia
- 14.3.1.8. Rest of Europe
- 14.3.2. By Product Type
- 14.3.3. By Indication
- 14.3.4. By Route of Administration
- 14.3.5. By Distribution Channel
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Product Type
- 14.4.3. By Indication
- 14.4.4. By Route of Administration
- 14.4.5. By Distribution Channel
- 14.5. Key Market Participants - Intensity Mapping
- 14.6. Drivers and Restraints - Impact Analysis
15. South Asia Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 15.3.1. By Country
- 15.3.1.1. India
- 15.3.1.2. Thailand
- 15.3.1.3. Indonesia
- 15.3.1.4. Malaysia
- 15.3.1.5. Rest of South Asia
- 15.3.2. By Product Type
- 15.3.3. By Indication
- 15.3.4. By Route of Administration
- 15.3.5. By Distribution Channel
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Product Type
- 15.4.3. By Indication
- 15.4.4. By Route of Administration
- 15.4.5. By Distribution Channel
- 15.5. Key Market Participants - Intensity Mapping
- 15.6. Drivers and Restraints - Impact Analysis
16. East Asia Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 16.3.1. By Country
- 16.3.1.1. China
- 16.3.1.2. Japan
- 16.3.1.3. South Korea
- 16.3.2. By Product Type
- 16.3.3. By Indication
- 16.3.4. By Route of Administration
- 16.3.5. By Distribution Channel
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Product Type
- 16.4.3. By Indication
- 16.4.4. By Route of Administration
- 16.4.5. By Distribution Channel
- 16.5. Key Market Participants - Intensity Mapping
- 16.6. Drivers and Restraints - Impact Analysis
17. Oceania Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 17.3.1. By Country
- 17.3.1.1. Australia
- 17.3.1.2. New Zealand
- 17.3.2. By Product Type
- 17.3.3. By Indication
- 17.3.4. By Route of Administration
- 17.3.5. By Distribution Channel
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Product Type
- 17.4.3. By Indication
- 17.4.4. By Route of Administration
- 17.4.5. By Distribution Channel
- 17.5. Key Market Participants - Intensity Mapping
- 17.6. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Biobetters Market Value (US$ Mn) Analysis 2019-2023 and Forecast 2024-2031
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 18.3.1. By Country
- 18.3.1.1. GCC Countries
- 18.3.1.2. Turkey
- 18.3.1.3. Northern Africa
- 18.3.1.4. South Africa
- 18.3.1.5. Rest of Middle East and Africa
- 18.3.2. By Product Type
- 18.3.3. By Indication
- 18.3.4. By Route of Administration
- 18.3.5. By Distribution Channel
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Product Type
- 18.4.3. By Indication
- 18.4.4. By Route of Administration
- 18.4.5. By Distribution Channel
- 18.5. Key Market Participants - Intensity Mapping
- 18.6. Drivers and Restraints - Impact Analysis
19. Market Structure Analysis
- 19.1. Market Analysis by Tier of Companies
- 19.2. Market Share Analysis of Top Players
- 19.3. Market Presence Analysis
- 19.3.1. By Regional footprint of Players
- 19.3.2. Product foot print by Players
- 19.3.3. Channel Foot Print by Players
20. Competition Analysis
- 20.1. Competition Dashboard
- 20.2. Competition Benchmarking
- 20.3. Competition Deep Dive
- 20.3.1. Amgen Inc.
- 20.3.1.1. Overview
- 20.3.1.2. Product Portfolio
- 20.3.1.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.1.4. Sales Footprint
- 20.3.1.5. Strategy Overview
- 20.3.1.5.1. Marketing Strategy
- 20.3.1.5.2. Product Strategy
- 20.3.1.5.3. Channel Strategy
- 20.3.2. F. Hoffmann-La Roche AG
- 20.3.2.1. Overview
- 20.3.2.2. Product Portfolio
- 20.3.2.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.2.4. Sales Footprint
- 20.3.2.5. Strategy Overview
- 20.3.2.5.1. Marketing Strategy
- 20.3.2.5.2. Product Strategy
- 20.3.2.5.3. Channel Strategy
- 20.3.3. Merck & Co. Inc.
- 20.3.3.1. Overview
- 20.3.3.2. Product Portfolio
- 20.3.3.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.3.4. Sales Footprint
- 20.3.3.5. Strategy Overview
- 20.3.3.5.1. Marketing Strategy
- 20.3.3.5.2. Product Strategy
- 20.3.3.5.3. Channel Strategy
- 20.3.4. Sanofi SA
- 20.3.4.1. Overview
- 20.3.4.2. Product Portfolio
- 20.3.4.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.4.4. Sales Footprint
- 20.3.4.5. Strategy Overview
- 20.3.4.5.1. Marketing Strategy
- 20.3.4.5.2. Product Strategy
- 20.3.4.5.3. Channel Strategy
- 20.3.5. SERVIER
- 20.3.5.1. Overview
- 20.3.5.2. Product Portfolio
- 20.3.5.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.5.4. Sales Footprint
- 20.3.5.5. Strategy Overview
- 20.3.5.5.1. Marketing Strategy
- 20.3.5.5.2. Product Strategy
- 20.3.5.5.3. Channel Strategy
- 20.3.6. Porton Biopharma Limited
- 20.3.6.1. Overview
- 20.3.6.2. Product Portfolio
- 20.3.6.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.6.4. Sales Footprint
- 20.3.6.5. Strategy Overview
- 20.3.6.5.1. Marketing Strategy
- 20.3.6.5.2. Product Strategy
- 20.3.6.5.3. Channel Strategy
- 20.3.7. Eli Lily and Company
- 20.3.7.1. Overview
- 20.3.7.2. Product Portfolio
- 20.3.7.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.7.4. Sales Footprint
- 20.3.7.5. Strategy Overview
- 20.3.7.5.1. Marketing Strategy
- 20.3.7.5.2. Product Strategy
- 20.3.7.5.3. Channel Strategy
- 20.3.8. Novo Nordisk A/S
- 20.3.8.1. Overview
- 20.3.8.2. Product Portfolio
- 20.3.8.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.8.4. Sales Footprint
- 20.3.8.5. Strategy Overview
- 20.3.8.5.1. Marketing Strategy
- 20.3.8.5.2. Product Strategy
- 20.3.8.5.3. Channel Strategy
- 20.3.9. Biogen Inc.
- 20.3.9.1. Overview
- 20.3.9.2. Product Portfolio
- 20.3.9.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.9.4. Sales Footprint
- 20.3.9.5. Strategy Overview
- 20.3.9.5.1. Marketing Strategy
- 20.3.9.5.2. Product Strategy
- 20.3.9.5.3. Channel Strategy
- 20.3.10. CSL Behring GmbH
- 20.3.10.1. Overview
- 20.3.10.2. Product Portfolio
- 20.3.10.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.10.4. Sales Footprint
- 20.3.10.5. Strategy Overview
- 20.3.10.5.1. Marketing Strategy
- 20.3.10.5.2. Product Strategy
- 20.3.10.5.3. Channel Strategy
- 20.3.11. Teva Pharmaceutical Industries Ltd.
- 20.3.11.1. Overview
- 20.3.11.2. Product Portfolio
- 20.3.11.3. Profitability by Market Segments (Product/Channel/Region)
- 20.3.11.4. Sales Footprint
- 20.3.11.5. Strategy Overview
- 20.3.11.5.1. Marketing Strategy
- 20.3.11.5.2. Product Strategy
- 20.3.11.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
